A 2025 clinical trial of ALZ-801 (valiltramiprosate) involving more than 300 adults age 50 or older who were genetically predisposed to Alzheimer's found that a subgroup of 125 participants with mild cognitive impairment at baseline showed a 52% slower rate of cognitive decline on one measured outcome compared with placebo.
October 29, 2025
high
statistical
Subgroup efficacy result from a 2025 randomized clinical trial of ALZ-801.
A 2025 clinical trial reported that participants treated with ALZ-801 experienced approximately 18% less hippocampal atrophy than placebo-treated participants.
October 29, 2025
high
statistical
Brain atrophy (hippocampal volume) comparison between ALZ-801 and placebo in a 2025 trial.
ALZ-801 is an oral medication administered twice daily that is designed to inhibit aggregation of beta-amyloid proteins to prevent formation of amyloid plaques, whereas monoclonal-antibody Alzheimer's therapies are administered intravenously, act primarily by promoting breakdown of existing amyloid plaques, and are associated with risks of brain swelling or bleeding.
October 29, 2025
high
descriptive
Comparative mechanisms of an oral anti-aggregation agent versus intravenous monoclonal-antibody therapies in Alzheimer's treatment.